Amgen’s top line has suffered from knockoff competition in recent quarters, and now the pain is moving to its payroll. After disclosing almost 150 cuts on the East Coast last week, the biotech giant now says it’s cutting 172 staffers at its headquarters and in the field.
The layoffs will hit R&D, operations and commercial employees, Amgen said in a California WARN filing (PDF). The majority of the jobs targeted are field-based jobs throughout the U.S., though some cuts will hit its headquarters in Thousand Oaks, California.
The layoffs will take effect Dec. 31, the filing said.
An Amgen spokeswoman said the company, like others, “regularly evaluates and adjusts staffing levels to meet the needs of the business.”
“While these decisions are never easy, we believe our ability to compete will be strengthened by a tighter focus on investments that can help bring important medicines to patients to treat serious, life-threatening illnesses,” she added.
The cuts come as Amgen deals with patent expirations and new biosimilar rivals. The company faces generic versions of its thyroid drug Sensipar and recently launched copycats to its white blood cell boosters Neupogen and Neulasta—plus anemia drug Epogen. Biosimilar versions of its immunology med Enbrel are approved but not yet launched. Amgen defeated a patent challenge on Enbrel from Sandoz over the summer.
Thanks to new rivals, the drugmaker’s sales dipped 2% in the second quarter and 3% in the third quarter versus the same periods last year.
Meanwhile, as biosims take a toll on its drugs, the company is hitting back with its own biosimilars to other companies’ blockbusters—and those meds brought in $173 million last quarter.
Last week, Amgen said it’d cut 149 jobs in Massachusetts by the end of the year as it exits neuroscience R&D.
Amgen in 2014 laid off 2,900 employees in a major restructuring, and the company in 2017 cut jobs as part of a plan to shift employment to a new facility in Tampa.
By Eric Sagonowsky
Source: Fierce Pharma
The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.
According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.
Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.